FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	$D \subset$	20540	
wasiiiigtoii,	D.C.	20549	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     O'Donnell Niall				2. Issuer Name and Ticker or Trading Symbol Reneo Pharmaceuticals, Inc. [ RPHM ]						(Ch	telationship eck all appli X Directo	,		son(s) to Iss				
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/06/2023								Officer below)	(give title		Other (s below)	pecify
C/O RENEO PHARMACEUTICALS, INC. 18575 JAMBOREE ROAD, SUITE 275-S				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person							
(Street)	C	A	92612											Form f Persor		e thar	One Repor	ting
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is interesting the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						hat is intende	d to						
		Tab	le I - No	n-Deriv	vative	Sec	curities	s Ac	quired, D	isp	osed o	of, or Be	neficial	ly Owne	d			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,		Code (Ins	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)			Benefici Owned	es Fially (I	Form (D) o	Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
							Code	v	Amount	(A) o (D)	r Price	Reporte Transac (Instr. 3	tion(s)			Instr. 4)		
		Т							uired, Dis , options					Owned				
1. Title of Derivative Security  (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Instr. 3)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)		Date,	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$9.01	06/06/2023			A		17,500		(1)	06/	/05/2033	Common Stock	17,500	\$0.00	17,500		D	

## **Explanation of Responses:**

1. The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

## Remarks:

/s/ Jennifer P. Lam, Attorneyin-Fact \*\* Signature of Reporting Person

06/08/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.